Machine learning approach to assess brain metastatic burden in preclinical models.

Journal: Methods in cell biology
Published Date:

Abstract

Brain metastases (BrM) occur when malignant cells spread from a primary tumor located in other parts of the body to the brain. BrM is a deadly complication for cancer patients and severely lacks effective therapies. Due to the limited access to patient samples, preclinical models remain a very valuable tool for studying metastasis development, progression, and response to therapy. Thus, reliable methods to assess metastatic burden in these models are crucial. Here we describe step by step a new semi-automatic machine-learning approach to quantify metastatic burden on mouse whole-brain stereomicroscope images while preserving tissue integrity. This protocol uses the open-source and user-friendly image analysis software QuPath. The method is fast, reproducible, unbiased, and gives access to data points not always accessible with other existing strategies.

Authors

  • Jessica Rappaport
    Inflammatory Cell Dynamics Section, Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research (CCR), National Cancer Institute (NCI), Bethesda, MD, United States.
  • Quanyi Chen
    Inflammatory Cell Dynamics Section, Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research (CCR), National Cancer Institute (NCI), Bethesda, MD, United States; Kelly Government Solutions, Bethesda, MD, United States.
  • Tomi McGuire
    Inflammatory Cell Dynamics Section, Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research (CCR), National Cancer Institute (NCI), Bethesda, MD, United States.
  • Amélie Daugherty-Lopès
    Inflammatory Cell Dynamics Section, Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research (CCR), National Cancer Institute (NCI), Bethesda, MD, United States. Electronic address: amelie.lopes@nih.gov.
  • Romina Goldszmid
    Inflammatory Cell Dynamics Section, Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research (CCR), National Cancer Institute (NCI), Bethesda, MD, United States. Electronic address: rgoldszmid@mail.nih.gov.